Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vardenafil - Respira Therapeutics

Next Previous
Search
Drug Profile

Vardenafil - Respira Therapeutics

Alternative Names: RT-234; RT234 AOS™ DPI; RT234-PAH

Latest Information Update: 07 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Respira Therapeutics
  • Developer Respira Therapeutics; United Therapeutics Corporation
  • Class Antifibrotics; Antihypertensives; Bronchodilators; Erectile dysfunction therapies; Imidazoles; Piperazines; Small molecules; Sulfones; Triazines
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • No development reported Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Pulmonary hypertension

Most Recent Events

  • 07 Apr 2022 Vardenafil - Respira Therapeutics receives Orphan Drug status for Pulmonary arterial hypertension in USA
  • 28 May 2021 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation, Powder)
  • 28 May 2021 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Inhalation, Powder)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top